<DOC>
	<DOC>NCT01256593</DOC>
	<brief_summary>The objective of this Investigation is to evaluate the safety and efficacy of Lyrica in medical practice. Also, occurrence of unknown and known adverse drug reactions (ADRs) in subjects treated with Lyrica will be monitored during the survey period, and whether an additional treatment outcome investigation and/or a post-marketing clinical study is required in the future will be determined.</brief_summary>
	<brief_title>Safety And Efficacy Of Lyrica (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>All the patients whom an investigator prescribes the first Lyrica® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Patients need to be administered Lyrica® in order to be enrolled in the surveillance. Patients not administered Lyrica®.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Lyrica</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
	<keyword>Safety</keyword>
	<keyword>Neuropathic Pain</keyword>
	<keyword>Post Marketing Surveillance</keyword>
</DOC>